Browse Category

Investing News 25 September 2025 - 26 September 2025

Electronic Arts Stock Skyrockets on $50 Billion Buyout Rumors – Latest Price & Outlook (Sept 2025)

Electronic Arts Stock Skyrockets on $50 Billion Buyout Rumors – Latest Price & Outlook (Sept 2025)

Conclusion and Outlook Electronic Arts finds itself at a pivotal moment. On one hand, the company’s fundamentals are solid – it has globally popular franchises, a growing stream of digital and recurring revenues, and a history of profitability and shareholder returns. Its stock performance has reflected that steady strength, with significant gains over the past year and hitting new records. On the other hand, the sudden buyout talks signal that outside investors see even more value (or untapped potential) in EA than the public markets have recognized. A $50 billion deal, if it comes, could reward current shareholders with a rapid
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Stock Price and Recent Performance Pfizer’s stock has struggled in 2025, hovering near multi-year lows. At ~$23.60 per share in late September, PFE has declined about 9% since January, underperforming the S&P 500 (which is up modestly) and lagging the broader healthcare sector. Over the past 12 months, the stock is down roughly 18%. The 52-week high was $30.43, and shares now sit not far above their year’s low of $20.92 stockanalysis.com. By market capitalization (~$134 billion), Pfizer remains one of the world’s largest pharmaceutical companies, but its valuation has compressed significantly from pandemic-era peaks. This underperformance stems largely from
AMPY Just Popped ~22% in a Day — Is Amplify Energy’s Rally For Real or a Head‑Fake? What the Fresh Data (Sept. 25–26) Really Shows

AMPY Just Popped ~22% in a Day — Is Amplify Energy’s Rally For Real or a Head‑Fake? What the Fresh Data (Sept. 25–26) Really Shows

In‑depth report What actually happened on Sept. 25–26 Price action: AMPY finished Sept. 25 at $5.84 (+21.67%), trading in a wide $5.17–$6.22 intraday range and posting ~13.5M shares in volume (vs. prior day ~0.54M). The step‑function move capped a three‑session upswing from $4.63 on Sept. 23. StockAnalysis Fresh discourse on Sept. 26: Before the market opened on Sept. 26, a widely read analysis argued that “large divestitures” could let Amplify “eliminate debt and focus on Beta development,” crystallizing the bull case investors have been nibbling at since August. Seeking Alpha Not a sector wave: The move occurred on a day
26 September 2025
SPRC Rockets 59% After “Quantum Leap”: What Really Drove SciSparc’s Two‑Day Surge (Sept. 25–26) — And What Comes Next

SPRC Rockets 59% After “Quantum Leap”: What Really Drove SciSparc’s Two‑Day Surge (Sept. 25–26) — And What Comes Next

Key facts (Sept. 25–26, 2025) What happened — and why it matters SciSparc’s new program aims to apply quantum algorithms to hard problems in protein folding and protein–ligand interactions, with the goal of more precise simulations that speed discovery in neurological and rare diseases. The board authorized creating a wholly‑owned Israeli subsidiary to run the effort and to pursue IP around the methods. GlobeNewswire The announcement comes alongside leadership changes disclosed in the same 6‑K: Amitay Weiss (formerly chair) moves into the President role, while Itschak Shrem becomes Chairman. Those shifts predate the quantum news (Sept. 21 resolution) but land in the same reporting
26 September 2025
NUAI Rockets Nearly 50% in a Day After AI Data‑Center Milestone—What Changed on Sept. 25–26 and What Could Break Next

NUAI Rockets Nearly 50% in a Day After AI Data‑Center Milestone—What Changed on Sept. 25–26 and What Could Break Next

Key facts (Sept. 25–26, 2025): What happened to NUAI on Sept. 25? Shares ripped ~50% into the close after fresh coverage amplified a Sept. 24 company release: Phase One engineering is done for TCDC, the JV aiming to develop a Permian Basin AI data‑center complex with behind‑the‑meter power “islands,” compliance with Texas SB6, and scalable capacity to 1 GW. Management says the milestone “validates the constructability” of the site and its power‑delivery path beginning in early 2027. Business Wire CEO E. Will Gray II put it bluntly: “We are de‑risking one of the most ambitious AI data center site developments
26 September 2025
Awe-Dropping Apple Event 2025 Shocks with Ultra-Thin iPhone 17 Air, New Watches & More

Apple’s 2025 Resurgence: iPhone 17 Supercycle Sparks AAPL Stock Surge to Record Highs

Full Overview of Apple Stock and Company News on September 25, 2025 Apple Stock Performance: From Slump to Surge in 2025 Apple’s stock performance in 2025 has been a tale of two halves. The year began on uncertain footing for the world’s most valuable company. Through the first half, AAPL lagged its Big Tech peers, with its share price sliding amid concerns about flagging iPhone demand and a lack of AI catalysts. By late July, Apple stock was down 17% year-to-date investopedia.com – a sharp contrast to the broader NASDAQ’s rally and the eye-popping gains of AI-centric names like NVIDIA.
26 September 2025
Oracle’s ‘Truly Awesome’ AI Cloud Quarter Sends Stock Soaring 36%, Making Ellison World’s Richest

Oracle’s $300 Billion AI Cloud Bombshell Sends ORCL Stock Soaring – What’s Next?

Oracle Stock Overview and Outlook as of September 25, 2025 Stock Performance (As of Sept 25, 2025) Oracle’s stock has been on a tear in 2025, massively outperforming the broader market. Shares started the year around $167 morningstar.com and climbed relentlessly on optimism around the company’s cloud and AI initiatives. By early September, ORCL nearly doubled in price – a year-to-date gain of over 85% reuters.com – making it one of the top performers in the S&P 500 and even outgaining high-flying peers like Apple, Microsoft, and Nvidia. On September 10, the stock hit an all-time closing high of $328.33
Battle of the EV Charging Standards: Tesla’s NACS vs. CCS2 vs. CHAdeMO – Who Will Rule the Roads in 2025?

Tesla Stock Takes a Hit After Europe Sales Crash – But Some Predict a $2 Trillion Future

Tesla showroom with Model S and Model 3 vehicles. Tesla’s stock has been on a rollercoaster in 2025 – surging on optimism around technology and growth, but hitting speed bumps from economic and competitive pressures benzinga.com benzinga.com. Recent Stock Performance and Momentum Tesla’s stock price has been on a rollercoaster in late 2025. As of September 25, TSLA sits around $425–$430, after sliding a few percent in today’s session benzinga.com. This mini-drop snapped a strong uptrend: over the prior month, Tesla had soared roughly 24%, significantly outperforming the market benzinga.com. In fact, earlier this week the stock hit its highest
25 September 2025
Nvidia’s Blockbuster July 2025: $4 Trillion Milestone, New Chips, and Global AI Power Plays

Nvidia (NVDA) Stock Soars on AI Mega-Deals – What’s Driving the Chip Giant in 2025?

NVDA Stock Price & Recent Movement (September 2025) Nvidia’s stock has been on a tear in 2025, reaching fresh highs on the back of the AI frenzy. On September 22, 2025, NVDA jumped about 3.9% in a single session to a record intraday high after announcing a massive OpenAI partnership reuters.com. That rally lifted Nvidia to roughly $184 per share – its highest level ever, and more than double its 52-week low stockanalysis.com. The surge crowned a multi-day run that pushed the major indexes to new records, with Nvidia leading the charge amid renewed tech euphoria. However, the stock saw
25 September 2025
RGC Stock Skyrockets 11,000% – Inside Regencell Bioscience’s Wild 2025 Ride

RGC Stock Skyrockets 11,000% – Inside Regencell Bioscience’s Wild 2025 Ride

In-Depth Report on RGC Stock as of September 25, 2025 Company Background & Fundamentals Regencell Bioscience’s Hong Kong office. The company is an early-stage biotech leveraging Traditional Chinese Medicine for neurological disorders. Founded in 2014 and listed on Nasdaq in 2021, Regencell focuses on developing natural TCM-based treatments for conditions like ADHD and autism spectrum disorder marketbeat.com. It has even explored herbal COVID-19 remedies in the past, though these remain experimental stocktitan.net. Importantly, RGC is pre-revenue – it has no product sales or FDA-approved drugs yet, and subsists on research funding (largely from its founder) and IPO proceeds. In the
Brookfield Business Partners (BBU) Soars on Structural Shake-Up – What Investors Need to Know

Brookfield Business Partners (BBU) Soars on Structural Shake-Up – What Investors Need to Know

BBU Stock Deep Dive as of September 25, 2025 Stock Price Performance Brookfield Business Partners’ stock has delivered robust gains in 2025, recently accelerated by the corporate streamlining news. As of Sept 25, 2025, BBU traded around $30–31 per unit, up from the high-$20s just a day earlier. On that day, shares gapped up from $28.48 to $31.34 at the open and spiked as high as ~$33 intraday marketbeat.com stockanalysis.com, before settling near $30.34 by afternoon marketbeat.com. This one-day jump of ~14–16% came on unusually high enthusiasm, marking a fresh 52-week high for the stock (previous yearly high was around
QMMM Stock Skyrockets 3,800% on Crypto Pivot – Crash or Comeback? (Sep 2025 Update)

QMMM Stock Skyrockets 3,800% on Crypto Pivot – Crash or Comeback? (Sep 2025 Update)

Latest Stock Price & Recent Performance Trends QMMM’s stock has been on a meteoric rise followed by a dramatic fall. In the second week of September, shares catapulted from penny-stock levels to over $200 in a single session – a +1,736% gain in one day finviz.com – after the company announced its cryptocurrency initiative. Intra-day on Sep 9, QMMM hit a high of $303 (a staggering +2,588% at peak) before closing that day at $207 finviz.com. That all-time high marked an increase of over 3,800% from just days prior finviz.com. This price surge was so extreme that trading was halted
Go toTop